Melatonin has become one of the most widely used sleep supplements in the United States. It is inexpensive, available without a prescription, and commonly viewed as a natural alternative to sleeping pills. Yet its popularity can obscure an important point: Melatonin is not a universal treatment for poor sleep. The evidence suggests that it is most useful when sleep problems involve the timing of the body’s internal clock, while its benefits for ordinary chronic insomnia are generally modest and inconsistent.
What Is Melatonin?
Melatonin is a hormone produced by the brain in response to darkness. Its primary role is to signal that biological nighttime has begun and help coordinate the circadian rhythm—the internal system that regulates sleep, alertness, body temperature, and other daily processes.
Supplemental melatonin therefore works differently from traditional sedatives. It does not simply “knock someone out.” Instead, it can shift or reinforce the timing of the sleep-wake cycle. This distinction helps explain why the supplement works better for some sleep problems than for others.
Read Also:
Melatonin and Chronic Insomnia
Chronic insomnia involves persistent difficulty falling asleep, remaining asleep, or obtaining restorative sleep despite having an adequate opportunity to rest. Studies of melatonin for this condition have produced mixed results.
Some trials and meta-analyses have found that melatonin can shorten the time required to fall asleep. However, the average improvement is usually modest, and effects on total sleep time, nighttime awakenings, sleep quality, and daytime functioning are less consistent. Differences in study populations, formulations, doses, and treatment schedules also make the research difficult to interpret.
Major sleep guidelines reflect this uncertainty. The American Academy of Sleep Medicine has issued a weak recommendation against using melatonin for sleep-onset or sleep-maintenance insomnia in adults, largely because the available evidence was considered very low quality and the measured benefits were not clinically meaningful. The 2023 European insomnia guideline similarly does not recommend immediate-release melatonin for insomnia in the general adult population.
An exception may be prolonged-release melatonin in adults aged 55 and older. European guidance allows it as a short-term option for this population, although the strength of the recommendation is moderate rather than definitive.
For chronic insomnia, cognitive behavioral therapy for insomnia, or CBT-I, remains the preferred initial treatment. CBT-I addresses the behaviors, schedules, and thought patterns that perpetuate insomnia and tends to produce more durable improvement than relying on a nightly supplement.
When Melatonin Is More Likely to Help
The strongest rationale for melatonin involves circadian-rhythm problems.
For example, people with delayed sleep-wake phase disorder naturally become sleepy and wake up much later than desired. Appropriately timed melatonin may move their internal clock earlier, particularly when combined with a consistent bedtime and correctly scheduled light exposure. Timing is critical: taking melatonin at the wrong point in the circadian cycle may provide little benefit or even shift the body clock in the undesired direction.
Melatonin can also reduce symptoms of jet lag, especially after travel across several time zones. Research suggests that it is generally more helpful for eastward travel, which requires the body clock to advance. Again, the time at which it is taken may matter as much as the amount.
Evidence for shift-work sleep problems is less convincing. Studies have been small and inconsistent, and melatonin cannot fully overcome the biological effects of working at night and sleeping during daylight hours.
Safety and Product Quality
Short-term melatonin use appears to be reasonably well tolerated by most healthy adults. Reported adverse effects include daytime sleepiness, headache, dizziness, nausea, and vivid dreams. Long-term safety is less certain because extended, high-quality studies are limited.
Melatonin can interact with medications and may require additional caution in people taking anticoagulants, those with epilepsy, and individuals who are pregnant or breastfeeding. Persistent sleepiness after taking it can also create risks when driving or operating equipment.
Product quality is another important concern. In the United States, melatonin is regulated as a dietary supplement rather than as a prescription or over-the-counter medication. Testing has found that some products contain substantially more or less melatonin than stated on the label. Some have also contained undeclared substances. Choosing an independently tested product may reduce, but not eliminate, this uncertainty.
Melatonin gummies must be stored securely. Their appearance and flavor make accidental ingestion by children more likely. Melatonin should not be given routinely to children without discussion with a pediatric clinician, particularly because evidence about long-term developmental effects remains incomplete.
The Practical Conclusion
Melatonin is best understood as a circadian-timing tool, not a powerful general sleeping pill. It may be useful for jet lag, delayed sleep timing, and selected patients with clearly defined sleep disorders. For routine chronic insomnia, however, the average benefit appears small, and addressing the underlying cause is more important.
Anyone with persistent insomnia, loud snoring, breathing pauses, restless legs, significant daytime sleepiness, depression, or reliance on sleep aids should seek a clinical evaluation. These symptoms may indicate a condition that melatonin will not correct. Better sleep often depends less on finding the strongest supplement and more on identifying the specific reason sleep has become disrupted.
Evidence
Melatonin helps regulate circadian timing, and evidence is more supportive for jet lag and delayed sleep-wake phase disorder than for generalized insomnia.
The American Academy of Sleep Medicine issued a weak recommendation against melatonin for adult sleep-onset or sleep-maintenance insomnia because the evidence was very low quality and benefits were not clinically significant.
The 2023 European guideline does not recommend immediate-release melatonin for general insomnia but permits prolonged-release melatonin for up to three months in patients aged 55 or older.
CBT-I is recommended as the initial treatment for chronic insomnia in adults.
Short-term adverse effects are generally mild, but long-term safety information is limited. Melatonin may also require caution with anticoagulants, epilepsy, pregnancy, breastfeeding, and other medications.
U.S. melatonin supplements are regulated differently from medications, and studies have documented substantial discrepancies between labeled and measured melatonin content.
Dr. Sara Michelson is a Licensed Psychologist in Chapel Hill N.C.
I am a doctoral-level licensed psychologist in Chapel Hill North Carolina; I have expertise in various evidence-based treatments for adults and am committed to providing scientifically validated interventions. I work with a diverse population, including trauma, insomnia, mood disorders, anxiety, and relationship problems. I take my work and clinical specializations seriously and continue to devote a considerable amount of time and effort to advance my training and professional development. For your convenience, my services are provided via telehealth.